West & Demouilpied – What now for the ATE market?

22nd August 2019
David Brown

David Brown

DAS UK Group

Underwriting Manager, ATE

In the recent Court of Appeal decision of West & Demouilpied, the court addressed the issues of reasonableness and proportionality, and the ‘proper’ approach to the assessment of costs – including ATE premiums.

It was a potentially huge moment for the ATE market, so I thought it might be useful to share my thoughts on the outcome, and break it down to its key elements; Demouilpied for Dummies, if you like.

The Background

Significantly, this was the first time an ATE premium had been scrutinised by the higher courts since Rogers v Merthyr Tydfil CBC in 2006. And whilst the decisions in West & Demouilpied focused on ARAG’s underwriting methodology, given the direct involvement of both DAS and LAMP in the Assessor’s hearing prior to the Appeal, this decision was always going to have wider ramifications for the market – and of course for the NHS.

It was anticipated that the decision would provide lower courts with much needed guidance on how to deal with the future assessment of ATE premiums in the post LASPO costs landscape.

The Decision

The bottom line is that ARAG was successful in recovering the ATE premiums associated with these cases in full, and there are a number of useful points to highlight that I think will assist the ATE market at large. The court:

  • Agreed that it is unacceptable for lower courts to make ad hoc, case-by-case decisions on cases if the premium has been block-rated;
  • Maintained that defendants cannot argue a premium is unreasonable by relying on photocopies of competitor premiums; expert evidence is required;
  • Conceded that they lacked the expertise to address whether a premium is reasonable, and to make that decision would put the whole market at risk;
  • Made it clear that block rated premiums – commonplace within the ATE market – cannot be reduced by referencing the value of the claim on a case by case basis; and
  • Acknowledged that if claimants are truly to be granted access to justice, then the continued existence of an ATE market to support this type of claim is of paramount importance.

The Impact

The impact of the decision remains to be seen, but here is what I think we can expect to see:

  • Greater certainty around how courts should approach premiums in the future, since judges in lower courts must have regard to this decision now;
  • Quicker resolution of costs and premium on future won cases;
  • The ATE industry having greater confidence around underwriting decisions in the future; and
  • Insurers who have considerable amounts of won but unpaid premiums now taking steps to encourage settlement of these premiums.

Whichever way you look at it, this will all be good news for access to justice, and a sustainable ATE market.

AvMA 2019: Women in law talk ATE

To mark the centenary of the Sex Disqualification (Removal) Act 1919, we got some female perspectives on ATE insurance and the role it plays in supporting access to justice.

June 2019 Learn more
AvMA 2019: The Evolution of ATE

With the AvMA Annual Clinical Negligence Conference (ACNC) taking place in Leeds this week, Robyn Lampon from DAS UK Group looks at how ATE insurance has evolved over the last 20 years.

June 2019 Learn more
A golden opportunity for ATE to innovate

Enrique Gomez, Head of ATE at DAS UK Group, looks at how the time is right for innovation in the ATE sector.

July 2018 Learn more

Read more from DAS

ATE Dispute resolution through the eyes of an ATE provider

Dispute Resolution (DR) has been a factor throughout our 22 years of providing ATE insurance.

April 2024
ATE Resolving healthcare disputes with sensitivity and efficiency

Ian Long from Browne Jacobson talks about the importance of approaching clinical negligence disputes with sensitivity and empathy.

April 2024
ATE Using mediation in clinical negligence cases

Alternative Dispute Resolution (ADR) in clinical negligence claims can take many forms, including mediation. Anna Sari from Morrish Solicitors explains.

April 2024
ATE What we have learned from 7 years of mediation

Paul Balen from Trust Mediation reflects on what he has found from his time working under the NHS Resolution Mediation Scheme.

April 2024
ATE The evolution of ATE

Nathan Holt, Head of ATE & BTE Underwriting at DAS, provides his unique view on an everchanging legal landscape and ATE’s role in providing access to justice.

December 2023
ATE 1,100 and counting – the rise of dispute resolution

Mediation and dispute resolution are on the rise, and are increasingly being preferred over court. Paul Balen, Director at Trust Mediation and Trust Arbitration, tells us more.

December 2023
ATE Fixed Recoverable Costs: is Jackson “finished”?

Nick McDonnell, Director at Kain Knight, looks at the Jackson reforms and what work remains to be done.

December 2023
ATE Looking back on 2023 & looking ahead to 2024 in ATE

Henrietta Hughes, Barrister at 3PB, looks back at developments in the road traffic and personal injury arena.

December 2023
ATE Empowering smaller legal practices: The success of the Optimise scheme

The Optimise scheme, launched by DAS and Maxima, has supported over 100 clients over the past two years, transforming the landscape for clinical negligence and personal injury cases.

October 2023
ATE The pros and cons of a Low Damages FRC (LD FRC) process in clinical negligence

Lisa O’Dwyer from Action against Medical Accidents looks at how the LDFRC process will affect Clinical Negligence claims.

September 2023
ATE Fixed Recoverable Costs is upon us

William Ellerton, Partner at DAS Law, gives his predictions for how the new FRC could play out.

September 2023
ATE How QOCS changes have affected a law firm

Matthew Olner, solicitor at Nelsons, talks about how the QOCS changes have affected his law firm.

June 2023
ATE QOCS changes: The ATE Provider’s Perspective

In this article, Rebecca Squires and Jane Marigold from DAS give their perspective on the QOCS changes.

June 2023